Related Experiment Videos
Reassessment of treatment modalities for paediatric patients with chronic immune thrombocytopenia
Hans-Jürgen Laws1, G Janssen, A Borkhardt
1Department of Paediatric Oncology, Haematology and Clinical Immunology, University Hospital, 40225 Duesseldorf, Germany. laws@med.uni-duesseldorf.de
Insights
Most children with immune thrombocytopenia (ITP) recover within six months. For chronic ITP, new therapies focus on stimulating platelet production, offering alternatives to splenectomy.
Area of Science:
- Pediatric Hematology
- Immunology
- Pharmacology
Background:
- Immune thrombocytopenia (ITP) affects children, with acute forms resolving within six months.
- Chronic ITP (cITP) is diagnosed if platelets remain low (<100,000/microl) for over 12 months, excluding other conditions.
- While spontaneous recovery occurs in 52% of children with cITP, treatment options for refractory cases with bleeding are limited.
Purpose of the Study:
- To review established and emerging therapeutic strategies for pediatric chronic immune thrombocytopenia (cITP).
- To explore pharmacological alternatives to splenectomy for managing refractory cITP in children.
Main Methods:
- Review of existing literature on pediatric ITP treatment guidelines.
- Analysis of therapeutic approaches including immunomodulation and platelet production stimulation.
- Discussion of rituximab as a potential treatment option.
Main Results:
- First-line therapy for bleeding ITP includes steroids or immunoglobulin.
- Splenectomy is a guideline-recommended treatment for refractory cITP, but pharmacological alternatives are sought.
- Rituximab shows promise as an effective treatment with few adverse effects.
Conclusions:
- Current treatment for cITP focuses on immunomodulation.
- Emerging research explores stimulating platelet production as a novel therapeutic avenue.
- Pharmacological alternatives to splenectomy, such as rituximab, are crucial for managing pediatric cITP.
Abstract:
Approximately 70% of children have the acute form of immune thrombocytopenia (ITP), which is defined by recovery within six months of presentation with or without treatment. Chronic ITP is to be reserved for patients with platelets < 100000/microl for more than twelve months and exclusion of other diagnosis like systemic lupus erythematosus or bone marrow failures. In children, the chance of spontaneous recovery is 52% after diagnosis of chronic ITP. The Intercontinental Childhood ITP Study group recommends that children without bleeding may not require therapy regardless of their platelet count. Whereas in patients with bleeding symptoms first line therapy is defined and includes steroids or immunoglobuline, second line therapy in refractory patients with significant hemorrhagic problems is unclear. Guidelines recommend splenectomy, but for more than 50 years patients and physicians look for pharmacological alternatives. It may be that rituximab is a promising option which has been proven to be effective with few adverse effects. Till now the treatment has focused on immunomodulation. Research has now focused on stimulating platelet production. In this review we discuss old and new therapy modalities for children with cITP.
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:22Myocarditis IV: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care
01:21Rheumatic Heart Disease III: Medical Management
01:18Endocarditis III: Medical Management